Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse DA, McIntyre L, et al. Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy. J Clin Oncol. 2020;38:3805–15. https://ascopubs.org/doi/abs/10.1200/jco.20.01467

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24. https://www.thelancet.com/article/S0140673621009338/fulltext

Article  CAS  PubMed  Google Scholar 

Munshi NC, Anderson LD Jr., Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. New Engl J Med. 2021;384:705–16.

Article  CAS  PubMed  Google Scholar 

Abramson JS, Solomon SR, Arnason JE, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. Blood. 2022;141:1675–84.

Article  PubMed Central  Google Scholar 

Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022;386:640–54.

Article  CAS  PubMed  Google Scholar 

Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019;54:1643–50.

Article  CAS  PubMed  Google Scholar 

Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020;4:3776–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wudhikarn K, Pennisi M, Garcia-Recio M, Flynn JR, Afuye A, Silverberg ML, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 2020;4:3024–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021;138:2499–513.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Logue JM, Peres LC, Hashmi H, Colin-Leitzinger CM, Shrewsbury AM, Hosoya H, et al. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022;6:6109–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023;141:2460–9.

CAS  PubMed  PubMed Central  Google Scholar 

Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, et al. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci Adv. 2023;9:eadg3919.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi AC, Barba P, et al. Immune effector cell-associated hematotoxicity (ICAHT): EHA/EBMT consensus grading and best practice recommendations. Blood. 2023;142:865–77.

Article  CAS  PubMed  Google Scholar 

Vic S, Thibert JB, Bachy E, Cartron G, Gastinne T, Morschhauser F, et al. Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome. A DESCAR-T study. Blood Adv. 2024;8:1573–85.

Article  PubMed  PubMed Central  Google Scholar 

Rejeski K, Greco R, Onida F, Sánchez-Ortega I, Bonini C, Sureda A, et al. An international survey on grading, diagnosis, and management of immune effector cell-associated hematotoxicity (ICAHT) following CAR T-cell therapy on behalf of the EBMT and EHA. Hemasphere. 2023;7:e889.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, et al. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 2024;

Schlegel RW, Smit AJ. heatwaveR: a central algorithm for the detection of heatwaves and cold-spells. J Open Source Softw. 2018;3:821.

Article  Google Scholar 

Smit AJ. Detect event streaks based on specified thresholds [Internet]. 2023 [cited 2023 Dec 20]. Available from: https://tangledbank.netlify.app/blog/2023-11-22-run-lengths/

CIBMTR. CIBMTR forms instructions manual: form 2100 revision 3 [Internet]. [cited 2024 Mar 7]. Available from: https://cibmtr.org/Files/Data-Operations/Retired-Forms-Manuals/2100r3-1.2017.pdf